High rates of hepatitis B virus (HBV) functional cure among HIV/HBV coinfected Chinese adults on antiretroviral therapy

Xia, Huan; Hu, Yue; Huang, Xiaojie; Wu, Hao; Ma, Ping

doi:10.1097/cm9.0000000000002501

Cited by 1 publication

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently, a study on patients co-infected with HBV/HIV from Tianjin revealed that after a median of 5.4 years of ART, predominantly using TDF-containing regimens, the rate of HBsAg seroclearance was 11.3%. [11] In our study, we observed an HBsAg seroclearance rate of 8.1% among the HBV/HIV co-infected patients, closely mirroring the findings of the Tianjin study. Additionally, our study showed an annual HBsAg seroclearance rate of 1.7 per 100 person-years, marginally exceeding the rate reported in the French cohort (1.5 per 100 person-years annually).…”

Section: Discussionsupporting

confidence: 88%

Incidence and factors associated with hepatitis B surface antigen seroclearance in patients co-infected with HBV/HIV during antiretroviral therapy in Guangdong, China

He,

Lin,

et al. 2023

Chinese Medical Journal

View full text Add to dashboard Cite

Background: Hepatitis B surface antigen (HBsAg) clearance is vital for a functional cure of hepatitis B virus (HBV) infection. However, the incidence and predictors of HBsAg seroclearance in patients co-infected with HBV and human immunodeficiency virus (HIV) remain largely unknown in Guangdong, China. Methods: Between 2009 and 2019, patients co-infected with HBV/HIV undergoing antiretroviral therapy (ART) in Guangzhou Eighth People's Hospital affiliated to Guangzhou Medical University were retrospectively reviewed with the endpoint being on December 31, 2020. The incidence and risk factors for HBsAg seroclearance were evaluated using Kaplan–Meier and multivariate Cox regression analyses. Results: A total of 1550 HBV/HIV co-infected patients were included in the study, with the median age of 42 years and 86.0% (1333/1550) males. Further, 98.3% (1524/1550) received ART containing tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC). HBV DNA was examined in 1283 cases at the last follow-up. Over the median 4.7 years of follow-up, 8.1% (126/1550) patients achieved HBsAg seroclearance, among whom 50.8% (64/126) obtained hepatitis B surface antibody, 28.1% (137/488) acquired hepatitis B e antigen seroconversion, and 95.9% (1231/1283) undetectable HBV DNA. Compared with patients who maintained HBsAg positive, cases achieving HBsAg seroclearance showed no differences in age, gender, CD4+ T cell count, alanine aminotransferase (ALT) level, or fibrosis status; however, they presented lower HBV DNA levels, lower HBsAg levels, and higher rates of HBV genotype B at the baseline. Multivariate analysis showed that baseline HBsAg <1500 cutoff index (COI) (adjusted hazard ratio [aHR], 2.74, 95% confidence interval [95% CI]: 1.48–5.09), ALT elevation >2 × upper limit of normal during the first six months after receiving ART (aHR, 2.96, 95% CI: 1.53–5.77), and HBV genotype B (aHR, 3.73, 95% CI: 1.46–9.59) were independent predictors for HBsAg seroclearance (all P <0.01). Conclusion: Long-term TDF-containing ART has high anti-HBV efficacy including relatively high overall HBsAg seroclearance in HBV/HIV co-infected patients. Lower baseline HBsAg levels, HBV genotype B, and elevated ALT levels during the first six months of ART are potential predictors of HBsAg seroclearance.

show abstract

Section: Discussionsupporting

confidence: 88%